Barrier Therapeutics Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Employees
-
130
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
6
Barrier Therapeutics General Information
Description
Developer and manufacturer of pharmaceuticals for dermatological therapeutics. The company provides Xolegel, a topical gel for the treatment of seborrheic dermatitis and Vusion, a topical ointment for the treatment of infants and children with diaper dermatitis.
Contact Information
Corporate Office
- 600 College Road East
- Suite 3200
- Princeton, NJ 08540
- United States
Corporate Office
- 600 College Road East
- Suite 3200
- Princeton, NJ 08540
- United States
Barrier Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Barrier Therapeutics Patents
Barrier Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20080032994-A1 | Adducts of 2,6-di-tert-butyl-4-methylphenol (bht) with azole compounds, e.g. ketoconazole, itraconazole, pramiconazole; skin fungal disorder associated with trichophyton, candida, pityrosporum or malassezia, or bacterial disorder associated with staphylococci, streptococci or propionbacterium acnes | Inactive | 03-Aug-2006 | ||
| ES-2571032-T3 | Itraconazole compositions with improved bioavailability | Active | 08-Aug-2005 | ||
| CA-2618255-C | Itraconazole compositions with improved bioavailability | Active | 08-Aug-2005 | ||
| CA-2618255-A1 | Itraconazole compositions with improved bioavailability | Active | 08-Aug-2005 | ||
| EP-1912625-A2 | Itraconazole compositions with improved bioavailability | Active | 08-Aug-2005 | A61K9/10 |
Barrier Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Barrier Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Barrier Therapeutics FAQs
-
When was Barrier Therapeutics founded?
Barrier Therapeutics was founded in 2001.
-
Where is Barrier Therapeutics headquartered?
Barrier Therapeutics is headquartered in Princeton, NJ.
-
What is the size of Barrier Therapeutics?
Barrier Therapeutics has 130 total employees.
-
What industry is Barrier Therapeutics in?
Barrier Therapeutics’s primary industry is Pharmaceuticals.
-
Is Barrier Therapeutics a private or public company?
Barrier Therapeutics is a Private company.
-
What is the current valuation of Barrier Therapeutics?
The current valuation of Barrier Therapeutics is .
-
What is Barrier Therapeutics’s current revenue?
The current revenue for Barrier Therapeutics is .
-
How much funding has Barrier Therapeutics raised over time?
Barrier Therapeutics has raised $172M.
-
Who are Barrier Therapeutics’s investors?
Aisling Capital, Baker-Tisch Investment Partners, CCMP Capital Advisors, Deerfield Capital, and J.P. Morgan are 5 of 11 investors who have invested in Barrier Therapeutics.
-
When was Barrier Therapeutics acquired?
Barrier Therapeutics was acquired on 07-Aug-2008.
-
Who acquired Barrier Therapeutics?
Barrier Therapeutics was acquired by Stiefel Laboratories.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
